AstraZeneca international biopharmaceutical company and K-SkAI, a resident of the Skolkovo Foundation, have signed a memorandum on the joint implementation of the project on Improving the diagnosis of chronic kidney disease through the development and implementation of a clinical decision support system.
Chronic non-communicable diseases claim millions of lives annually, lead to severe complications, disability, reduced quality of life and the need for expensive therapy. Chronic kidney disease (CKD) occupies an important place among these diseases. Detection of CKD during its early stages is an important task and largely depends on the vigilance and competence of general practitioners, physicians, family doctors and cardiologists.
The goal of the project is to improve early detection of CKD through the analysis of electronic health records using the Webiomed healthcare artificial intelligence platform.
The Webiomed platform analyzes the data of the patient's electronic health record, automatically determines risk factors and provides physians with actionable recommendations.
The platform works only with depersonalized medical data in order to predict the possible development of diseases and their complications both at the personal and population levels. For two years that the system is in operation, data from about 200 million medical documents were analyzed. The service processes over 20,000 requests daily.
Astrazeneca and K-SkAI have been implementing joint projects since 2020. At the end of last year, a collaborative study was concluded that examined the prevalence, severity and treatment outcomes of patients with chronic kidney disease based on a retrospective analysis of real-world data (RWD). The result of the project was published in the article "Prevalence Of Chronic Kidney Disease According To The Retrospective Cohort Study “CKD Epidemiology” by Batiushin M.M., Kasimova I.S., Gavrilov D.V., Gusev A.V., Gulamov A.A. in the Nephrology and Dialysis journal.
Anonymized medical data was analyzed using machine learning technologies in order to identify the relationship between individual facts. Clinical and demographic characteristics, clinical outcomes, and current treatment regimens for patients with CKD were analyzed.
As part of the joint project, the companies will conduct large-scale retrospective studies based on the analysis of electronic health records of patients using machine learning models validated on data from each region.
Our joint project is aimed at identifying the development of a dangerous pathology - chronic kidney disease, which has a high mortality rate not only in the Russian Federation. Together with AstraZeneca, we will use advanced technologies and artificial intelligence to detect patients with CKD at an early stage, which will allow them to adjust their treatment in time. We thank AstraZeneca for their trust. We will continue our cooperation, - stated Andrey Salikov, Webiomed Chief Commercial Officer.
In Russia, about 27 million people suffer from chronic kidney disease, and only 3 million are aware of their diagnosis. The problem of underdiagnosis of CKD is a heavy burden on the healthcare system, resulting in a decrease in the quality of life and disability of millions of patients. To solve this problem, pharmaceutical companies are not limited to the development and production of drugs, today they are looking for integrated approaches to therapy and screening. We hope that the joint project with K-SkAI will help Russian patients receive a diagnosis and start treatment on time, - commented Anna Brashchenkova, medical director of AstraZeneca’s Biopharma in Russia and Eurasia.
The joint project of K-SkAI and AstraZeneca is an illustrative example of the work of the Skolkovo Foundation ecosystem. Such partnerships, especially in the field of artificial intelligence technologies and big data processing, are an absolute priority for the Foundation. We welcome the desire of K-SkAI, our resident company, to actively cooperate with the leaders of the pharmaceutical market and leading domestic medical experts in terms of solving strategic national tasks in the field of healthcare such as prevention, early detection and reduction of morbidity. The Skolkovo Foundation hopes for the successful implementation and replication of the project,- claimed Yulia Shcheglova, Project Manager of the Biomedical Technologies Cluster of the Skolkovo Foundation.
About AstraZeneca
AstraZeneca is an international, science-driven biopharmaceutical company focused on the research, development and marketing of prescription drugs primarily in therapeutic areas such as oncology, cardiology, nephrology and metabolism, respiratory and autoimmune diseases.
Based in Cambridge, UK, AstraZeneca is present in more than 100 countries and its innovative products are used by millions of patients around the world. Website: https://www.astrazeneca.ru/.
About the Skolkovo Foundation
The Skolkovo Foundation is a non-profit organization established in 2010. It acts as the managing company of the Skolkovo Innovation Center. The purpose of the Fund is to support technological entrepreneurship in Russia and commercialize the results of research activities. The number of Skolkovo residents has already exceeded 3,000. The Foundation provides them with a range of services necessary to bring developments to the Russian and international markets. Resident status gives the company tax and customs benefits. In 2020, the revenue of residents exceeded 160 billion rubles. Since 2019, the law allows any organization engaged in research activities in Russia to gain access to all services and benefits of the Innovation Center. The Skolkovo Institute of Science and Technology (Skoltech), one of the top 100 young universities in the world according to Nature Index, is located on the territory of the Skolkovo Innovation Center. The infrastructure of the Innovation Center consists, in particular, of the largest Technopark in Europe and research centers of industrial partners. In 2019, three new partner R&D centers were opened in the Innovation Center by Sibur, TMK and Tatneft companies. On the territory of Skolkovo, a total of more than 760 thousand square meters are already being used as residential areas, research and educational centers. Extra-budgetary investments in the creation of infrastructure exceeded 100 billion rubles. Website: https://sk.ru
Currently, the Government of the Russian Federation is transforming the system of development institutions, which provides for their integration into the management coverage of VEB.RF. On the basis of VEB.RF, a centralized investment unit is being created to implement projects that contribute to the achievement of national development goals. The priority of VEB.RF Group is the consolidation of public and private investment resources for the breakthrough development of the country, improving the quality and creating comfortable conditions for people's lives.